2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
135
Carcinoma, Hepatocellular
81
Neoplasms
53
Small Cell Lung Carcinoma
51
Breast Neoplasms
50
Lung Neoplasms
45
Triple Negative Breast Neoplasms
41
Colorectal Neoplasms
39
Melanoma
38
Carcinoma, Transitional Cell
37
Urinary Bladder Neoplasms
33
Neoplasm Metastasis
32
Carcinoma, Renal Cell
30
Ovarian Neoplasms
20
Uterine Cervical Neoplasms
19
Stomach Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
17
Head and Neck Neoplasms
15
Liver Neoplasms
14
Prostatic Neoplasms
13
Glioblastoma
12
Solid Tumors
11
Recurrence
11
Sarcoma
10
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Lymphoma
9
Kidney Neoplasms
9
Endometrial Neoplasms
9
Mesothelioma, Malignant
8
Interventions
Drug Therapy
2
tremelimumab
1
pembrolizumab
1
enfortumab vedotin
1
durvalumab
1
atezolizumab
1
Watchful Waiting
1
Radiotherapy
1
Palliative Care
1
Magnetic Resonance Spectroscopy
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle-invasive Bladder Cancer
×
atezolizumab
×
Clear all
NCT04660344
2026-03-27
IMvigor011
Hoffmann-La Roche
Phase 3
Active not recruiting
761 enrolled
1 FDA